213 related articles for article (PubMed ID: 34297443)
1. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
2. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
4. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
6. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
7. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
9. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
12. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract][Full Text] [Related]
13. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
14. [A Case of de novo Neuroendocrine Prostate Cancer].
Kise H; Shiraishi T
Hinyokika Kiyo; 2021 Mar; 67(3):113-118. PubMed ID: 33957032
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
[TBL] [Abstract][Full Text] [Related]
16. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy in the management of neuroendocrine prostate cancer.
Martínez-Cornelio A; González-Pérez J; Tabares-García Fde J; Ramos-Salgado F; Alvarado-Cabrero I; Hernández-Toriz N
Cir Cir; 2009; 77(4):293-9; 273-8. PubMed ID: 19919791
[TBL] [Abstract][Full Text] [Related]
18. Intraductal Carcinoma of the Prostate without High-Grade Invasive Adenocarcinoma: Report of Two Cases and Review of the Literature.
Ortiz-Rey JA; Bellas-Pereira A; San Miguel-Fraile P; Morellón-Baquera R; Domínguez-Arístegui P; González-Carreró Fojón J
Arch Esp Urol; 2022 Nov; 75(9):738-745. PubMed ID: 36472055
[TBL] [Abstract][Full Text] [Related]
19. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
20. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]